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T1DM onset in 9 patients and after the onset of T1DM in 8). 
Height SDS patterns during GH therapy in the 11 patients af-
fected by GH deficiency ranged from –0.3 to +3.1 SDS. In the 
8 diabetic patients in whom GH was added subsequently, 
mean insulin dose increased during the first 6 months of 
therapy from 0.7 ± 0.2 to 1.0 ± 0.2 U/kg (p = 0.004). HbA 1c was 
unchanged during the first 6 months of combined therapy. 
 Conclusions: Most Italian physicians do not consider pre-
scribing the combined GH-insulin therapy in diabetic chil-
dren with growth problems. However, the results of the 17 
patients identified would confirm that the combined thera-
py was feasible and only caused mild insulin resistance. GH 
therapy was effective in promoting growth in most patients 
and did not affect diabetes metabolic control. 
 © 2014 S. Karger AG, Basel 
 Key Words 
 Growth hormone · Insulin therapy · GH deficiency · 
Type-1 diabetes · Turner syndrome 
 Abstract 
 Background/Aim: Combined growth hormone (GH) and in-
sulin therapy is rarely prescribed by pediatric endocrinolo-
gists. We investigated the attitude of Italian physicians to 
prescribing that therapy in the case of short stature and 
type-1 diabetes (T1DM).  Methods: A questionnaire was sent 
and if a patient was identified, data on growth and diabetes 
management were collected.  Results: Data from 42 centers 
(84%) were obtained. Of these, 29 centers reported that the 
use of combined therapy was usually avoided. A total of 17 
patients were treated in 13 centers (GH was started before 
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 Introduction 
 Combined growth hormone (GH) and insulin therapy 
are rarely prescribed in pediatric patients. Apart from the 
recent multicenter German study describing 37 children 
treated with insulin and GH  [1] , so far only single case 
reports have been published dealing with both pediatric 
or adult patients  [2–6] . The infrequency of this combined 
treatment is probably due to two main reasons. The first 
is purely statistical, since the possibility of the double as-
sociation type-1 diabetes (T1DM) and GH deficiency 
(GHD) is extremely unlikely: the estimated prevalence, in 
fact, is between 1: 2,000 and 1: 5,000 for GHD, the most 
frequent disease where GH therapy is prescribed in chil-
dren, and 1: 800 for T1DM  [7] . The second probably aris-
es from the concerns in managing a multiple daily injec-
tion treatment involving two hormones having opposite 
effects on glucose metabolism. Finally, despite the reas-
suring published data that GH treatment is not associated 
with an increased incidence of T1DM  [8, 9] , the discor-
dant results on the possible increased incidence of T2DM 
in GH-treated children have probably represented a fur-
ther obstacle in prescribing the two hormones simultane-
ously  [8–10] .
 To investigate the attitude of Italian Pediatric endocri-
nologists to treating patients simultaneously with GH 
and insulin, in the first part of 2012 a questionnaire was 
sent to all members of the Italian Society for Pediatric and 
Adolescent Endocrinology (ISPED). In cases where a pa-
tient was identified, specific details were requested for 
each case. The primary aim of the survey was, therefore, 
to test the general attitude of the participants towards the 
double therapy and, secondly, to collect data on the man-
agement of insulin therapy, growth outcome and possible 
side effects of the identified patients.
 Materials and Methods 
 A questionnaire was sent by e-mail to all 480 members of the 
ISPED, belonging to 52 centers around the country. The first part 
of the questionnaire enquired about the general attitude of the pe-
diatric endocrinologists to prescribing the combined therapy, and 
the second concerned the database of information on the patients, 
if any. Two possibilities were considered: (1) that an already dia-
betic child required GH for short stature and (2) that T1DM oc-
curred in a child in the course of GH therapy. The only inclusion 
criterion to identify a patient was based on the combined therapy 
for at least 6 months with insulin (due to T1DM) and GH (due to 
any type of growth impairment). Exclusion criteria were hypergly-
cemia not due to T1DM and therapy with antidiabetic oral agents. 
 The questionnaire contained the following questions:
 (1)  In the last 20 years, have you ever treated a patient with GH 
and insulin who fulfilled the inclusion criteria? 
(2)  If no, is the reason because (a) you never had a similar patient, 
(b) you did not consider GH treatment in an already diabetic 
child or (c) you stopped GH therapy after the onset of T1DM? 
 Only if a patient was identified were specific data asked. The 
patients were subdivided into 2 groups: (1) patients with onset of 
T1DM first and subsequent start of GH therapy and (2) patients 
already treated with GH and subsequent onset of T1DM. In both 
cases the file included information on the growth of the subject 
before treatment, at the end of GH treatment or (if therapy was still 
ongoing) at the last visit and, finally, on final height if reached. 
Furthermore, the reasons for treating the patient with GH, the du-
ration of the combined treatment and the type of insulin therapy 
were also included. In the patients with onset of T1DM first, spe-
cific data on variations in insulin doses and degree of metabolic 
control after GH was started were collected. In the patients with 
GH as first treatment, further data were asked on the interval be-
fore diabetes onset, possible transient withdrawal from GH thera-
py and the type of insulin therapy chosen.
 T1DM was diagnosed according to the International Society 
for Pediatric and Adolescent Diabetes (ISPAD) criteria  [11] . The 
diagnosis of GHD was performed following the Italian NHS, com-
bining auxological criteria and a GH peak <10 ng/ml after 2 phar-
macological stimuli. Other diseases in which GH is permitted as a 
promoting agent are Turner syndrome and small-for-gestational-
age children. In selected cases, after obtaining permission from the 
local ethical committees, GH therapy was prescribed for other con-
ditions associated with short stature not due to the aforementioned 
reasons.
 GH and HbA 1c were determined locally using various commer-
cial kits and results of HbA 1c of the patients described were per-
formed with DCCT-centerd methods. The Italian standards by 
Cacciari et al.  [12] were used to determine height SDS.
 Results 
 Data were obtained from 42 centers (84%), 13 of which 
identified 17 patients fulfilling the inclusion criteria; 1 
center treated 3 patients and 2 centers treated 2 patients 
each.
 More than two-thirds of the centers (29/42; 69%) stat-
ed that the use of combined therapy was considered un-
comfortable and therefore to be avoided. They reported 
either to never have had a patient with a simultaneous 
diagnosis of GHD and T1DM (26 centers) or to not con-
sider GH therapy for any problem affecting growth in an 
already diabetic patient. Three centers reported on 3 pa-
tients treated for GHD withdrawal from GH therapy after 
the diagnosis of T1DM. In contrast, 13 centers reported 
the treatment of 17 patients (9 males, 8 females). In the 
whole group of patients, mean height at GH therapy start 
was –2.9 ± 0.7 SDS, mean age at T1DM onset was 7.6 ± 
4.3 years and mean age at GH therapy start 8.0 ± 3.3 years.
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 Table  1 shows the clinical characteristics of the pa-
tients in whom GH therapy was started before the diag-
nosis of T1DM. As shown, most patients were treated for 
isolated GHD, whereas 1 patient had multiple pituitary 
hormone deficiency (GH, TSH, ACTH, gonadotrophins), 
1 patient had secondary GHD due to cranial irradiation 
for non-Hodgkin lymphoma and 1 girl had Turner syn-
drome. The patient with multiple pituitary deficiencies 
showed a poorly visible pituitary stalk and hypoplastic 
anterior lobe at the MRI. In 2 patients of this group GH 
therapy was transiently withdrawn (1 month in patient 
No. 1 and 6 months in patient No. 8) after the diagnosis 
of T1DM and then restarted. In all patients but 1 the di-
agnosis and GH treatment was started before the age of 
10 years. As shown, the time period between the start of 
GH therapy and the onset of T1DM ranged from 1 month 
to 7 years. The duration of GH therapy was highly vari-
able, ranging from 24 to 180 months (still ongoing in 2 
cases), and height SDS patterns from the start to the end 
of therapy ranged from –0.3 to +2.3 SDS in the patients 
with GHD. In the 5 patients who already reached final 
height, height gain from GH therapy start ranged from 
+0.4 SDS (patient No. 2 with isolated GHD) to +3.9 SDS 
(patient No. 5 with organic GHD). GH dosages were not 
modified after the diagnosis of T1DM.
 Table 2 describes the patients with an initial diagnosis 
of T1DM and a subsequent start of GH therapy. As shown, 
GH therapy was started for GHD in only 3 patients, where-
as in the remaining patients it was chosen to correct short 
stature associated with Turner syndrome, for bone dys-
 Table 1.  Characteristics of the 9 patients in whom GH therapy was started before T1DM onset
No. Sex Reason for
GH therapy
Age at
GH therapy
start, years
Age at 
T1DM onset,
years
GH peak,
ng/ml
Height 
SDS at 
GH start
Height 
SDS at 
GH stop
Final
height SDS
GH dose,
mg/kg/week
Duration of
GH therapy,
months
1 M GHD 12 13 7.7 –2.6 –2.9 not reached 0.21 24
2 F GHD 3.6 8.8 3 –2.3 –1.3 –1.9 0.2 112
3 M GHD 2.5 2.6 5.9 –3.1 –0.8 pending 0.2 84 ongoing
4 M GHD 6.1 6.6 9 –3.5 –2.6 pending 0.2 33 ongoing
5 F organic GHD 9.3 13.1 3 –3.1 –1.1 +0.8 0.2 27
6 F Turner 
syndrome
6 7 not done –2.8 –1.30 not reached 0.4 63
7 F GHD 6 13 6.3 –3.7 –2.6 –2.6 0.25 24
8 M GHD 8 9 4 –2.6 –1.1 –1.4 0.2 30
9 M MPHD 3 13 2.1 –3.3 –3.2 –2.7 0.3 180
 GH therapy is still ongoing in cases No. 3 and 4. MPHD = Multiple pituitary hormone deficiency.
 Table 2.  Characteristics of the 8 patients in whom GH therapy was started after T1DM onset
No. Sex Reason for GH therapy Age at
T1DM
onset,
years
Age at GH 
therapy
start, years
GH peak, 
ng/ml
Height 
SDS at
GH start
Height 
SDS at
GH stop
Final
Height 
SDS
GH dose,
mg/kg/
week
HbA1c
at GH 
start, %
HbA1c after 
6 months of 
combined 
therapy, %
Duration of
GH therapy,
months
10 M GHD 8 11 6.4 –3.2 –1.9 –2.3 0.20 7.4 7.3 60
11 F ISS 12.1 13.7 20 –2.5 –1.3 –1.3 0.26 7.2 7.6 18
12 M Bone dysplasia 1.0 10.5 7.7 –2.9 –2.6 pending 0.26 9.4 8.5 18 ongoing
13 F Léri-Weill syndrome 9.6 10.1 12 –2.5 –3.5 pending 0.28 8.1 8.1 12 ongoing
14 F GHD 2.5 9.5 6.4 –3.2 –0.1 pending 0.21 8.3 8 46 ongoing
15 M GHD 3.3 5 3.7 –3.0 –2.7 pending 0.22 7 7.1 13 ongoing
16 F Turner syndrome 1.7 11.5 not done –3.9 –3.9 –3.9 0.30 7.1 6.8 84
17 F Turner syndrome 5.6 8.7 not done –0.9 –0.9 pending 0.27 8.5 7.9 6 ongoing
 GH therapy is still ongoing in cases No. 12–15 and 17. ISS = Isolated short stature.
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plasias and in 1 case for isolated short stature. In only 2 
patients was GH therapy started before the age of 10 years. 
The time period between the onset of T1DM and start of 
GH therapy ranged from 6 months to almost 10 years. The 
duration of GH therapy ranged from 6 to 84 months (still 
ongoing in 5 cases) and height gain SDS from the start to 
the end of therapy ranged from +0.3 to +3.1 SDS in the 
patients with GHD. Height gain from GH therapy start in 
the 3 patients who already reached final height ranged 
from 0 SDS in the patient with Turner syndrome to +1.2 
SDS in the patient with isolated short stature.
 Figure 1 shows height SDS patterns during GH thera-
py of the 9 patients with isolated GHD, the patient with 
multiple hormone pituitary deficiency and the patient 
with organic GHD (therapy was ongoing in 4 cases).
 As for diabetes management, insulin therapy was per-
formed with MDI in 11 patients and with CSII in the re-
maining 6. In the latter patients the pediatric diabetolo-
gist reported that the choice was based on the better man-
agement of nocturnal hyperglycemia following GH 
administration due to the possibility of increasing the 
nocturnal basal rate. In the patients already affected by 
T1DM at GH therapy start, the mean insulin dose in-
creased during the first 6 months after GH start from 
0.7 ± 0.2 to 1.0 ± 0.2 U/kg (p = 0.004) and in 1 patient (No. 
8;  table 1 ) the insulin requirement increased from 0.3 to 
0.8 U/kg soon after GH therapy was started after the tran-
sient withdrawal. HbA 1c was unchanged in these patients 
during the first 6 months of combined therapy (pre-GH 
values: 7.9 ± 0.8 vs 7.7 ± 0.6%, p = 0.91). No significant 
side effects related to GH therapy were reported and com-
pliance to GH therapy was recorded as good in all cases.
 Discussion 
 Although combined therapy with insulin and GH was 
rarely performed by Italian pediatric endocrinologists, we 
were able to collect data of 17 children treated in the last 
20 years, in whom GH was not only used as a replacement 
therapy but also as a growth-promoting agent despite the 
simultaneous presence of T1DM. We could identify op-
posite attitudes among Italian pediatric endocrinologists 
towards the combined therapy: in fact, about two-thirds 
of the physicians declared avoiding the double treatment 
and three of them specifically reported to have withdrawn 
GH therapy after the diagnosis of diabetes. Other centers, 
on the other hand, used the combined therapy also out-
side the field of strict replacement therapy, by starting it 
even after the diagnosis of T1DM. To justify the attitude 
of many Italian colleagues to avoiding the combined ther-
apy, one must consider the fact that insulin is a life-saving 
therapy, whereas GH is not. It is likely, therefore, that in 
the case of T1DM onset after the start of GH therapy, par-
–4
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 Fig. 1. Height SDS patterns during GH 
therapy of the 9 patients with isolated 
GHD, the patient with multiple hormone 
pituitary deficiency and the patient with 
organic GHD (therapy was ongoing in 4 
cases). 
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ents and caregivers had to cope with the difficult task of 
adapting to the new lifestyle (requiring a multiple daily 
injection treatment after the new diagnosis), with the 
problem of short stature becoming less important. 
 Many physicians were probably also influenced by the 
notorious antagonist effect of GH on insulin action  [12–
14] , which is probably thought to make the management 
of T1DM insulin therapy difficult, especially during the 
pubertal years. Interestingly enough, in 3 centers GH 
therapy was withdrawn in 3 patients affected by isolated 
GHD after the diagnosis of diabetes, while this was not the 
case for the 9 patients described in  table  1 . Despite the 
recent and reassuring data on the lack of increase of T1DM 
incidence in children treated for GH, the fact that GH 
therapy increases insulin resistance and T2DM incidence 
in predisposed individuals  [8–10] may have acted as a 
subtle psychological deterrent for any physician. The final 
judgment on this matter largely depends not only on the 
attitude of the physician, but also on the height of the child 
at the time of T1DM diagnosis and on the family reaction 
in the face of the second diagnosis. Our survey is in partial 
agreement with the recent German-Austrian collaborative 
study that identified 50 patients from a large national 
database treated with both insulin and GH therapy  [1] . 
The collaborative study was specifically designed to 
evaluate insulin requirement and metabolic control in 37 
children with T1DM in whom GH therapy was added to 
insulin subsequently, but indirectly provided evidence 
that our colleagues are even less reluctant to prescribe GH 
therapy in an already diabetic child: although the 37 
patients described in that study were derived from a large 
national database, our survey of only 7 patients with GH 
started after the diagnosis of T1DM ( table 2 ) included 42 
Italian centers (84%) that are likely to follow most of the 
patients affected by growth problems or T1DM. 
 In our study and in the German-Austrian study, it is 
demonstrated that insulin therapy during GH therapy 
can be managed with adequate titration of insulin dosage. 
In both case series HbA 1c remained unchanged after GH 
therapy start ( table 2 ) and the insulin requirement was 
quite surprisingly similar (1 U/kg) in the 2 investigations, 
where both multiple daily injections and pumps were 
used. In our study, the pump was preferred to the injec-
tion regimen in about a third of cases to better manage 
the nocturnal insulin resistance consequent to the GH ad-
ministration. Insulin regimens for all children with 
T1DM have improved consistently in the last years and, 
thanks to the availability of different insulin analogs and 
also of pumps, it is possible to tailor the insulin schedule 
for almost every child and clinical condition. 
 The growth response to GH therapy obtained in our 
relatively small group of patients affected by different 
diagnosis, treated for different periods of times with 
standard GH doses in most cases, was roughly comparable 
to that described in the literature for the various types of 
growth disturbances  [15] . Despite being highly variable in 
the different diagnostic groups and despite the different 
therapy durations (still ongoing in 7 patients), height 
patterns ranged from –0.3 to 3.1 SDS in the patients with 
GHD; the more homogeneous group of patients with 
GHD is depicted in figure 1 . This result shows that GH 
therapy was more effective than that reported by the 
 German-Austrian study (mean value +0.3 SDS after 
2 years of GH therapy), indicating that perhaps diabetes 
itself is not the cause of a poor response to GH therapy and 
that the growth response is more dependent on the type of 
disease that affects the patient. In fact, compared to the 
German patients, who were all affected by isolated GHD, 
our patients were on average significantly younger and 
consistently shorter – parameters with a known positive 
influence on growth response to GH. Also, poor compliance 
to GH therapy, a known parameter with a negative 
influence on growth response, should also be considered 
as a possible determinant of insufficient growth. 
 A similar good response was reported in the pediatric 
case described by Quintos et al.  [5] where, in terms of sta-
tistical exceptionality, the patient resembles our case af-
fected by T1DM and multiple pituitary hormone defi-
ciency. To our knowledge, no patients affected by multi-
ple hormone deficiencies developing T1DM during 
replacement therapy have been described. 
 In conclusion, our survey demonstrated that many 
physicians from Italian centers of pediatric endocrinology 
do not consider combined therapy with GH and insulin 
in a diabetic child with growth problems. At the same 
time, the results obtained from the 17 patients described 
would confirm that GH therapy is feasible in diabetic chil-
dren and caused only mild insulin resistance. In our case 
series GH was effective in promoting growth in most pa-
tients and did not affect diabetes metabolic control. 
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